A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Status:
Completed
Trial end date:
2017-02-22
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and clinical activity of long-term
dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being
followed-up for safety.